# Acute Pulmonary Embolism

Acute pulmonary embolism requires probability-guided testing, rapid assessment for cardiopulmonary failure, immediate anticoagulation when indicated, and selective escalation to reperfusion therapy. Contemporary multisociety guidance emphasizes integrated clinical, hemodynamic, respiratory, biomarker, and right-ventricular assessment to guide disposition and treatment.

**Clinical question:** How should adults with suspected or confirmed acute pulmonary embolism be diagnosed, risk stratified, treated, and dispositioned?

Updated: 2026-08-21T00:25:06.241317+00:00

## What matters in practice
- Use clinical pretest probability before D-dimer or imaging; CTPA is the principal diagnostic test, while V/Q scanning is useful when CTPA is contraindicated or unavailable. [22]
- D-dimer thresholds adjusted for clinical probability can reduce unnecessary CTPA while maintaining a low subsequent risk of venous thromboembolism in appropriately selected patients. [2]
- After diagnosis, determine whether the patient has persistent hypotension or cardiopulmonary failure, then incorporate clinical severity, biomarkers, and right-ventricular assessment to guide site of care and escalation. [6][7]
- Symptomatic patients with elevated clinical severity, biomarker elevation, and/or right-ventricular dysfunction should be hospitalized; persistent hypotension identifies the highest-acuity category. [7]
- Advanced reperfusion or interventional strategies require individualized risk-benefit assessment and are most relevant in hemodynamically significant PE or clinical deterioration. [10][11][12][13]

## Identify cardiopulmonary failure before completing the diagnostic pathway

Hemodynamic status determines urgency, feasible testing, monitoring intensity, and need for reperfusion planning.

In suspected acute PE, first establish whether shock, cardiac arrest, persistent hypotension, or evolving cardiopulmonary failure is present. The 2026 multisociety guideline organizes acute PE severity using clinical, hemodynamic, respiratory, biomarker, and right-ventricular parameters, progressing from asymptomatic disease through low-severity symptomatic PE, elevated-severity PE, incipient cardiopulmonary failure, and persistent-hypotension cardiopulmonary failure. [6][7]

For an unstable patient in whom CTPA is not feasible, bedside echocardiography is an accepted adjunctive diagnostic strategy; it should support urgent management rather than delay resuscitation or definitive imaging when feasible. [22]
- Obtain focused hemodynamic and respiratory assessment immediately; persistent hypotension or cardiopulmonary failure warrants hospital-level escalation and consideration of advanced therapy pathways. [7][12][13]
- Assess for alternative immediately life-threatening diagnoses in parallel, particularly acute coronary syndrome, aortic disease, tamponade, pneumothorax, and sepsis; the supplied sources do not provide a validated differential-diagnosis algorithm.
- Engage a multidisciplinary pulmonary embolism response team when there is shock, impending decompensation, major bleeding complexity, or uncertainty regarding catheter-based or surgical therapy; standardized PERT algorithms have been implemented to guide evaluation, management, and disposition. [18]

*Disposition-oriented acute PE clinical categories described in the 2026 multisociety guideline-at-a-glance. [7]*

| Clinical category | Key features described in source | Disposition implication |
| --- | --- | --- |
| A | Asymptomatic acute PE. [7] | May be discharged directly from the emergency department. [7] |
| B | Symptomatic PE with low clinical severity score. [7] | Early hospital discharge is generally recommended. [7] |
| C | Symptomatic PE with elevated clinical severity score, including elevated biomarkers and/or right-ventricular dysfunction. [7] | Hospitalize to optimize treatment. [7] |
| D | Incipient cardiopulmonary failure. [7] | Hospitalize and optimize treatment strategy. [7] |
| E | Cardiopulmonary failure characterized by persistent hypotension. [7] | Hospitalize; urgent advanced management assessment is indicated by acuity. [7][12][13] |

## Use pretest probability to select D-dimer or imaging

Avoid indiscriminate imaging by matching testing to clinical probability and imaging feasibility.

CT pulmonary angiography is the primary diagnostic test for acute PE across major guidelines. V/Q scanning is preferred or useful when CTPA is contraindicated or unavailable. [22] The choice should account for contrast exposure, renal function, radiation considerations, local access, and whether another chest diagnosis is likely to be clarified by CTPA; specific thresholds for these considerations are not provided in the supplied sources.

D-dimer is most useful when the pretest probability is not high. A prospective management study evaluated D-dimer thresholds adjusted for clinical pretest probability with the goal of reducing unnecessary CTPA while identifying patients who can safely avoid anticoagulation and imaging. [2] Do not use a negative D-dimer result as a stand-alone exclusion strategy without first establishing a low or intermediate clinical probability framework.

In patients with confirmed PE, evaluate prognosis beyond clot location. Current approaches integrate clinical severity assessment with biomarkers and imaging evidence of right-ventricular abnormality. PESI or simplified PESI remain commonly used validated clinical risk tools in guideline-based practice. [22]
- Hemodynamically stable patient: estimate clinical pretest probability, then use D-dimer selectively or proceed to definitive imaging according to probability and local protocol. [2][22]
- CTPA contraindicated or unavailable: use V/Q imaging when appropriate. [22]
- Unstable patient unable to undergo CTPA: use bedside echocardiography as an adjunct while managing presumed high-risk PE and pursuing definitive evaluation when feasible. [22]
- After PE confirmation: obtain clinical severity assessment and evaluate biomarkers and right-ventricular size/function because these findings influence hospitalization and escalation decisions. [6][7][22]

### Biomarkers and prognosis

Natriuretic peptides and troponin identify myocardial stress or injury and can refine risk assessment in hemodynamically stable PE. In an outpatient-focused guideline review, NT-proBNP below 500 pg/mL was associated with favorable outcomes in selected patients discharged within 24 hours, whereas elevated BNP or NT-proBNP was associated with higher 30-day mortality in a cited meta-analysis. [3] These data support prognostic refinement, not substitution for the full clinical assessment.
- In a cited cohort of selected stable patients, those meeting outpatient eligibility criteria with NT-proBNP below 500 pg/mL had no death, recurrent VTE, or major bleeding through 3 months after discharge within 24 hours. [3]
- Biomarker elevation should be interpreted with clinical severity and right-ventricular evaluation rather than as an isolated trigger for reperfusion. [6][7][22]

*Testing approach based on the supplied guideline summaries and diagnostic study. [2][22]*

| Clinical context | Preferred next diagnostic step | Practical interpretation |
| --- | --- | --- |
| Stable patient with suspected PE | Apply a clinical probability assessment before selecting D-dimer or imaging. [2][22] | Clinical probability determines whether D-dimer-based exclusion is appropriate or imaging should proceed directly. [2] |
| Need for definitive chest vascular imaging | CTPA. [22] | CTPA is the primary diagnostic modality across major PE guidelines. [22] |
| CTPA contraindicated or unavailable | V/Q scan. [22] | V/Q imaging is the guideline-supported alternative in this setting. [22] |
| Hemodynamic instability and CTPA not feasible | Bedside echocardiography as an adjunct. [22] | Use findings to support urgent management; do not delay stabilization. [22] |

## Separate low-risk PE from patients at risk for early decompensation

Disposition depends on symptoms, clinical severity, cardiopulmonary reserve, right-ventricular burden, biomarkers, and practical outpatient safety.

Validated clinical scores, particularly PESI and simplified PESI, are used to identify lower-risk patients after PE confirmation. [22] The 2026 multisociety framework further emphasizes that clinical severity should be interpreted alongside respiratory status, hemodynamics, cardiac biomarkers, and right-ventricular size and function. [6][7]

Outpatient management is not simply a low clot-burden decision. It requires low predicted early complication risk, no need for reperfusion or inpatient supportive care, acceptable bleeding risk, reliable medication access, and follow-up infrastructure. The newer multisociety summary supports emergency department discharge for asymptomatic PE and generally supports early discharge for symptomatic patients with low clinical severity. [7]
- Consider early discharge only after confirming low clinical severity and ensuring outpatient feasibility; use institutional criteria rather than a score alone. [7][22]
- Hospitalize patients with elevated clinical severity, right-ventricular dysfunction, elevated biomarkers, incipient cardiopulmonary failure, or persistent hypotension. [7]
- Monitor hospitalized intermediate-severity patients for worsening oxygenation, blood pressure, perfusion, and evidence of progressive right-heart failure; exact monitoring intervals and triggers are not specified in the supplied sources.

## Initiate anticoagulation promptly once PE is confirmed or strongly suspected

Anticoagulation is the core treatment, while reperfusion is reserved for selected high-acuity presentations.

The purpose of diagnostic evaluation is to identify patients with PE who are expected to benefit from anticoagulant treatment and to avoid treatment in patients without PE or with disease unlikely to progress. [2] Contemporary PE guidance includes pharmacologic therapy across acute and early post-acute care, but the supplied search results do not provide drug-specific U.S. dosing, renal adjustments, duration recommendations, or selection criteria among direct oral anticoagulants, heparins, and warfarin. [6]

Use an anticoagulant regimen consistent with current institutional protocols, FDA labeling, and patient-specific factors including hemodynamic stability, anticipated invasive therapy, renal function, hepatic disease, pregnancy, active cancer, drug interactions, adherence, and bleeding risk. These selection details require source verification because they are not specified in the supplied excerpts.
- Do not delay anticoagulation for routine disposition decisions after PE is diagnosed unless a contraindication or an imminent reperfusion procedure changes the immediate plan. The supplied sources support prompt treatment conceptually but do not provide operational timing or dosing. [2][21]
- For patients being considered for catheter-based therapy, surgery, or systemic fibrinolysis, coordinate anticoagulant management with the treating team; specific peri-procedural regimens are not available from the supplied results. [11][12]
- Reassess bleeding risk and concurrent antithrombotic therapy before selecting or continuing anticoagulation; detailed contraindication lists are not supplied.

## Reserve reperfusion strategies for hemodynamically significant PE or deterioration

Systemic fibrinolysis, catheter-based treatment, and surgical embolectomy require rapid multidisciplinary selection.

Patients with PE presenting with shock, arrest, or persistent hypotension have the clearest need for urgent consideration of reperfusion and advanced support strategies. Earlier AHA statements and interventional reviews describe systemic fibrinolysis, catheter-assisted embolectomy, surgical embolectomy, and, in selected circumstances, IVC filter placement as advanced treatment options. [10][11][12][13]

For normotensive patients with right-ventricular dysfunction or biomarker elevation, routine escalation should not be inferred from either finding alone. The newer framework distinguishes elevated-severity PE from incipient cardiopulmonary failure and persistent-hypotension failure, reinforcing the need to identify clinical trajectory rather than treating all intermediate-risk phenotypes alike. [6][7]

Catheter-directed and mechanical interventions have expanded, but patient selection remains a central uncertainty. The supplied sources establish their role as available options and emphasize appropriate risk stratification; they do not provide sufficiently detailed comparative outcomes, device-specific indications, or contraindication criteria to support prescriptive device selection. [11][15]
- Persistent hypotension, shock, arrest, or progressive cardiopulmonary failure: urgently involve critical care, cardiology, interventional, surgical, and/or PERT resources as locally available. [7][12][13]
- Intermediate-severity PE: hospitalize, monitor closely, and escalate if there is clinical deterioration or failure of supportive management; biomarker or right-ventricular abnormalities alone should be integrated with the whole clinical picture. [6][7]
- IVC filters are described among advanced therapies in older statements, but the supplied sources do not provide current indications; do not use these excerpts to justify routine filter placement. [10]

*Advanced treatment options referenced in AHA and interventional PE documents. [10][11][12][13]*

| Strategy | Most relevant clinical setting | Evidence limitation in supplied sources |
| --- | --- | --- |
| Systemic fibrinolysis | Hemodynamically significant PE, especially shock or arrest. [12][13] | No current dosing, contraindication, or comparative-outcome details are provided. [10][12] |
| Catheter-assisted embolectomy or catheter-directed therapy | Selected patients requiring advanced treatment after multidisciplinary assessment. [10][11] | The supplied excerpts do not support device-specific patient selection. [11][15] |
| Surgical embolectomy | Selected severe PE when urgent reperfusion is required. [10][12][13] | Specific timing, surgical criteria, and outcomes are not supplied. [12][13] |
| IVC filter | Listed as an advanced option in older AHA material. [10] | Current indication criteria are not provided; routine use cannot be supported from supplied sources. [10] |

## Plan follow-up around symptoms, anticoagulant safety, and persistent functional limitation

Follow-up is part of acute PE management, particularly after early discharge.

The 2026 multisociety guideline addresses care from symptom onset through clinical follow-up and includes acute and early post-acute management. [6] Patients discharged early require a defined follow-up plan that verifies anticoagulant access and adherence, reassesses bleeding and recurrent-thrombosis symptoms, and evaluates persistent dyspnea or functional limitation.

Persistent symptoms after PE should prompt evaluation for alternative cardiopulmonary disease and, when clinically appropriate, chronic thromboembolic pulmonary hypertension. The supplied sources identify chronic thromboembolic pulmonary hypertension as a PE-related management domain but do not provide a follow-up interval or diagnostic algorithm. [13][19]
- At follow-up, reassess symptoms, functional status, bleeding, medication adherence, and complications of anticoagulant therapy; specific intervals are not available in the supplied sources.
- Investigate persistent or worsening dyspnea rather than attributing it automatically to post-PE recovery; chronic thromboembolic disease is an important consideration. [13][19]

## Common questions

### When should a D-dimer be ordered for suspected pulmonary embolism?

Order D-dimer within a structured clinical pretest-probability strategy, principally when probability is not high and a negative result could avoid imaging. Probability-adjusted D-dimer strategies have been studied to reduce unnecessary CTPA. [2][22]

### What is the preferred imaging test for acute pulmonary embolism?

CTPA is the principal diagnostic imaging test across major PE guidelines. Use V/Q scanning when CTPA is contraindicated or unavailable; use bedside echocardiography as an adjunct in unstable patients when CTPA cannot be performed. [22]

### Which patients with acute pulmonary embolism can be discharged early?

The 2026 multisociety summary supports emergency department discharge for asymptomatic PE and generally recommends early discharge for symptomatic patients with low clinical severity, provided outpatient treatment is feasible and safe. [7]

### Does right-ventricular dysfunction mandate thrombolysis in pulmonary embolism?

No. Right-ventricular dysfunction and biomarker elevation identify higher-risk patients who should generally be hospitalized, but escalation should incorporate hemodynamics, respiratory status, clinical trajectory, and bleeding risk. [6][7]

### When should a pulmonary embolism response team be involved?

Consider PERT involvement for shock, persistent hypotension, incipient cardiopulmonary failure, anticipated reperfusion therapy, complex bleeding risk, or uncertainty between catheter-based and surgical options. [7][11][18]

## References
1. - IIER - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf
2. Diagnosis of Pulmonary Embolism with d-Dimer Adjusted ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1909159
3. British Thoracic Society Guideline for the initial outpatient ... — thorax.bmj.com — https://thorax.bmj.com/content/73/Suppl_2/ii1
4. Pulmonary Embolism — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMcp2116489
5. British Thoracic Society guidelines for the management of ... — thorax.bmj.com — https://thorax.bmj.com/content/58/6/470
6. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/ ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.11.005
7. 2026 Acute Pulmonary Embolism Guideline-at-a-Glance — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.12.023
8. The AHA/ACC Guideline for Pulmonary Embolism: A New Era in Diagnosis, Risk Assessment, and Management — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.12.089
9. 2026 Acute Pulmonary Embolism Guideline Hub — www.jacc.org — https://www.jacc.org/guidelines/acute-pulmonary-embolism
10. Management of Submassive Pulmonary Embolism — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circulationaha.110.961136
11. Interventional Therapies for Acute Pulmonary Embolism — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000707
12. Interventional Treatment of Pulmonary Embolism | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circinterventions.116.004345
13. Management of Massive and Submassive Pulmonary ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0b013e318214914f
14. Acute pulmonary embolism: I. Review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/0002870367905108
15. Treatment of acute pulmonary embolism: a comparison ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1538783625009006
16. Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children: A Review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0012369221040575
17. Major Pulmonary Embolism: Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0012369216447276
18. Standardization of Pulmonary Embolism Evaluation and ... — academic.oup.com — https://academic.oup.com/milmed/article/188/7-8/e1808/6763644
19. 2019 ESC Guidelines for the diagnosis and management of ... — academic.oup.com — https://academic.oup.com/eurheartj/article/41/4/543/5556136
20. 2014 ESC Guidelines on the diagnosis and management ... — academic.oup.com — https://academic.oup.com/eurheartj/article/35/43/3033/503581
21. First AHA/ACC acute pulmonary embolism guideline — www.acc.org — https://www.acc.org/about-acc/press-releases/2026/02/19/19/27/first-ahaacc-acute-pulmonary-embolism-guideline-prompt-diagnosis-and-treatment-are-key
22. Cover Story | Pulmonary Embolism: A Clinical Approach — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2025/02/01/42/cover-story-pulmonary-embolism
23. 2019 ESC Guidelines for Acute Pulmonary Embolism - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/09/04/13/39/2019-esc-guidelines-for-acute-pulmonary-embolism
24. Pulmonary Embolism Guideline Comparison: Key Points — www.acc.org — https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2024/10/07/15/41/international-clinical-practice

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.